Sign in
CompletedNo phase

Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
United Arab Emirates4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
63 people enrolled
Started
28 Apr 2025
Ended
16 Jul 2026
Type of study
Observational
Treatments tested
  • Secukinumab
Record updated
12 November 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
  • Male or Female adult patients ≥ 18 years of age at the time of data collection
  • Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent)
  • Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion
  • Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion
  • Agreed to sign an informed consent to be able to fill in the questionnaires

Who cannot take part

  • Patients not fulfilling any of the abovementioned inclusion criteria
  • Patient's refusal to be included in the study or refusal to sign the informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region.

The group in the trial

  • Secukinumab

    Patients who are newly initiated on treatment with Secukinumab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab in Routine Clinical Practice in the United Arab Emirates: ILLUMINATE-HS, a Prospective Patient Surve
Record updated
12 November 2026